Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 1/2 3Phase NA 1

Status

Terminated 1Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Other solid neoplasm 1Gynecologic 1

Conditions

Ovarian Neoplasms 1Multiple Myeloma 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumors 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Interventional × Maximum Tolerated Dose × Clear all
NCT05976555 2026-05-20

Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma

Medical College of Wisconsin

Phase 1 Not yet recruiting
30 enrolled
Plasma cell

Multiple Myeloma

NCT06976892 2025-08-13

IDOL

Institute of Cancer Research, United Kingdom

Phase 1 Recruiting
33 enrolled
Gynecologic

Ovarian Neoplasms

NCT02994953 2024-09-20

COMBO

EMD Serono

Phase 1 Terminated
52 enrolled 34 charts
Other solid neoplasm

Advanced Solid Tumors

NCT01647711 2017-01-31

A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations

Boehringer Ingelheim

Phase 1 Completed
35 enrolled 13 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡